Patents by Inventor John Desjarlais

John Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric antibodies that bind CD3 and PSMA
    Patent number: 11623957
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: April 11, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu
  • TRISPECIFIC ANTIBODIES
    Publication number: 20230086017
    Abstract: Provided herein are trispecific antibodies that include a) a first monomer, b) a second monomer, and c) a light chain. The first monomer includes a first variant Fc domain and a variable heavy domain, the second monomer includes a second variant Fc domain and a first scFv domain and the light chain includes a variable light domain. The variable heavy domain and the variable light domain form an antigen binding domain. The trispecific antibody further includes a second scFv domain on either the first or second monomers.
    Type: Application
    Filed: July 22, 2022
    Publication date: March 23, 2023
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
  • HETERODIMERIC PROTEINS
    Publication number: 20230059206
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Application
    Filed: March 23, 2022
    Publication date: February 23, 2023
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
    Patent number: 11584794
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
    Publication number: 20230041377
    Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Application
    Filed: September 28, 2022
    Publication date: February 9, 2023
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20220403049
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: May 4, 2022
    Publication date: December 22, 2022
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
    Patent number: 11524991
    Abstract: The present invention is directed to novel PD-1-targeted IL-15/R?-Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R?-Fc fusion proteins can be administered to a patient to treat cancer.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 13, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20220380462
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: June 4, 2021
    Publication date: December 1, 2022
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • IL-7-FC-fusion proteins
    Patent number: 11512122
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 29, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
    Patent number: 11505595
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: November 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • Bispecific checkpoint inhibitor antibodies
    Patent number: 11492407
    Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: November 8, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal
  • ENGINEERED IL-2 Fc FUSION PROTEINS
    Publication number: 20220213162
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: Matthew BERNETT, John DESJARLAIS, Rajat VARMA, Rumana RASHID
  • BISPECIFIC AND MONOSPECIFIC ANTIBODIES USING NOVEL ANTI-PD-1 SEQUENCES
    Publication number: 20220204624
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
    Publication number: 20220195048
    Abstract: The present invention is directed to novel IL15/IL15R? heterodimeric Fc fusion proteins.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 23, 2022
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20220162343
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 3, 2021
    Publication date: May 26, 2022
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Engineered IL-2 Fc fusion proteins
    Patent number: 11319355
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 3, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • Bispecific and monospecific antibodies using novel anti-PD-1 sequences
    Patent number: 11312770
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 26, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Heterodimeric proteins
    Patent number: 11299554
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 12, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
    Publication number: 20220073588
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 10, 2022
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz